Transarterial chemoembolization combined with immunotherapy plus bevacizumab or lenvatinib for the treatment of unresectable hepatocellular carcinoma: which treatment strategy demonstrates superior efficacy?

ABSTRACT:

SUBMITTER: Kang W 

PROVIDER: S-EPMC12521020 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature